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Quality of life (QL) is an important consideration when comparing adjuvant therapies for early breast cancer, especially if they differ
substantially in toxicity. We evaluated QL and Q-TWiST among patients randomised to adjuvant dose-intensive epirubicin and
cyclophosphamide administered with filgrastim and progenitor cell support (DI-EC) or standard-dose anthracycline-based
chemotherapy (SD-CT). We estimated the duration of chemotherapy toxicity (TOX), time without disease symptoms and toxicity
(TWiST), and time following relapse (REL). Patients scored QL indicators. Mean durations for the three transition times were
weighted with patient reported utilities to obtain mean Q-TWiST. Patients receiving DI-EC reported worse QL during TOX,
especially treatment burden (month 3: Po0.01), but a faster recovery 3 months following chemotherapy than patients receiving
SD-CT, for example, less coping effort (Po0.01). Average Q-TWiST was 1.8 months longer for patients receiving DI-EC (95% CI,
 2.5 to 6.1). Q-TWiST favoured DI-EC for most values of utilities attached to TOX and REL. Despite greater initial toxicity, quality-
adjusted survival was similar or better with dose-intensive treatment as compared to standard treatment. Thus, QL considerations
should not be prohibitive if future intensive therapies show superior efficacy.
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Patient-reported quality of life (QL) during adjuvant chemother-
apy for early breast cancer shows transient adverse effects during
therapy, but it improves after cessation of standard therapy
(Hurny et al, 1996; Fairclough et al, 1999; de Haes et al, 2003;
Bernhard et al, 2004, 2007; Land et al, 2004; Martin et al, 2005),
dose-intensive therapy (Del Mastro et al, 2002), or high dose
therapy (Macquart-Moulin et al, 2000; Brandberg et al, 2003;
Peppercorn et al, 2005). Overall QL improves substantially over the
first 2 years (Hurny et al, 1996). There is some evidence that dose-
dense chemotherapy may be more effective than standard doses
(Citron et al, 2003), but the impact of such therapy on the QL has
not been studied.
For women with early-stage breast cancer and a high risk of
relapse, the International Breast Cancer Study Group (IBCSG)
compared three cycles of adjuvant dose-intensive epirubicin and
cyclophosphamide chemotherapy administered with filgrastim and
progenitor cell support (DI-EC) with four courses of standard-dose
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santhracycline-based chemotherapy followed by three courses of
classical CMF (SD-CT) in a randomised clinical trial (Basser et al,
2006). There was a nonsignificant trend in favour of DI-EC with
respect to disease-free survival. The patients were faced with two
markedly different treatment regimens, the shorter dose-intensive
chemotherapy requiring prolonged or repeated hospitalisation and
the standard therapy of more than double duration as outpatient
treatment.
Patients reported indicators of QL longitudinally after com-
mencement of chemotherapy. We also evaluated trade-offs by
performing a quality-adjusted survival analysis based on utilities
derived from patient-reported health status (Hurny et al, 1998),
including periods while they were receiving adjuvant therapy, the
disease-free interval and, where appropriate, after relapse.
PATIENTS AND METHODS
The trial
Between July 1995 and March 2000, 344 women with operable
breast cancer from centres in Europe, Australia, and Asia were
enrolled in IBCSG Trial 15–95 (Figure 1A). Patients were
randomised within 6 weeks after surgery and the randomised
treatment was to commence within 10 weeks. Standard dose
chemotherapy consisted of intravenous injections of doxorubicin
60mgm
 2 or epirubicin 90mgm
 2 and cyclophosphamide
600mgm
 2 (AC or EC) every 3 weeks for four cycles. This was
immediately followed by oral cyclophosphamide 100mgm
 2 daily
for 14 days, and intravenous injections of methotrexate 40mgm
 2
and fluorouracil 600mgm
 2 on days 1 and 8 (‘classical’ CMF),
every 4 weeks for three cycles. In the DI-EC regimen, peripheral
blood progenitor cells were collected before chemotherapy.
Filgrastim 10mgkg
 1 was given subcutaneously daily for 6 days
with leukapheresis on days 5, 6, and 7 of administration.
Chemotherapy consisted of epirubicin 200mgm
 2 intravenously
over 1h on day 1 and cyclophosphamide 4gm
 2 on day 2, given
as 1gmm
 2 intravenously over 30min in four divided doses.
Dose-intensive doxorubicin and cyclophosphamide was given
every 3 weeks for three cycles. All patients were assigned to
receive tamoxifen 20mg per day through 5 years once chemo-
therapy had finished.
Informed consent was obtained from all patients, and the
institutional review committee at each participating centre
approved the study. The details of the trial protocol and conduct
are described elsewhere (Basser et al, 2006).
Quality of life
The protocol required that all patients participate in the QL study.
Patients were asked to complete a QL assessment on day 1 of each
cycle of chemotherapy. In order to have assessments at
approximately the same time points as in the SD-CT group,
patients randomised to receive DI-EC were asked to fill in two
baseline assessments, one on day 1 of Filgrastim and another on
day 1 of the first EC cycle. To assess morbidity associated with
treatment, we report QL data for the first 18 months following
randomisation in patients without recurrence within this time
(Figure 1B).
The original hypothesis (1995) was that patients receiving DI-EC
have a worse QL than those receiving SD-CT for at least 24 months.
On the basis of later findings (Macquart-Moulin et al, 2000; Del
Mastro et al, 2002; Brandberg et al, 2003; Peppercorn et al, 2005),
we predicted worse QL during DI-EC as compared to SD-CT but
a rapid recovery and no treatment-related differences 3 months
after completion of chemotherapy. No formal power calculations
were made at the time the study was initiated. Coping effort
(Hurny et al, 1993) had been selected as the primary end point.
This global indicator (‘How much effort does it cost you to cope
with your illness?’) in the linear analogue self-assessment (LASA)
format was selected due to its responsiveness to chemotherapy,
changes over time on and off treatment (Hurny et al, 1996), and
psychological distress (Bernhard et al, 2001).
Aspects of QL were assessed by the IBCSG QL core ques-
tionnaire (Bernhard et al, 1997) comprising single-item LASA
indicators for physical well-being, mood, coping effort, appetite,
tiredness, hot flushes, nausea/vomiting, perceived social support,
restrictions in arm movement, and subjective health estimation
(SHE) (Hurny et al, 1998). In addition, a trial-specific module for
the first 9 months after randomisation included LASA indicators
for hair loss, numbness, thought of actually having treatment, loss
of sexual interest or ability, all based on GLQ-8 (Coates et al, 1990),
sore mouth, and pain. Finally, two global LASA indicators were
included in the trial-specific module, one for overall treatment
burden (Bernhard et al, 2002) (‘Overall, how much are you
bothered by any treatment related difficulties?’) and an ad hoc
item of functional performance (‘How well do you perform your
daily activities as compared with the time before your breast
operation?’). The burden indicator has shown itself to be less
precise for specific toxicity effects but responsive to the whole
spectrum of treatment sequelae (Bernhard et al, 2002).
Completing and submitting a baseline QL assessment before
randomisation was not an eligibility requirement. As a result, 87%
of the patients with a baseline QL assessment completed the form
after knowing their assigned treatment. As a substantial number of
patients completed their baseline assessment after randomisation,
we did not test for differences in QL scores between baseline and
subsequent time points.
A linear mixed-effects model assuming a spatial covariance
structure was used to estimate and describe treatment effects of QL
over time and at specific time points. This model used all the QL
information obtained on the patient while allowing for the
repeated measurements to exhibit correlation between observa-
tions attributable to within the subject. Missing QL data were
assumed to be missing at random. We used the square roots
of the QL scores to reduce skewing and to stabilise the variances
for all indicators. The figures show the results on the original scale
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Standard chemotherapy (SD-CT)
Dose-intensive EC (DI-EC)
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Menopausal status
ER status
Institution
DI-EC
Figure 1 International Breast Cancer Study Group Trial 15–95 schema
(A). Three hundred forty-four patients were randomised to receive either
standard dose chemotherapy (AC or EC 4 followed by CMF 3) or
dose-intensive EC 3. All patients were assigned tamoxifen. DI-EC, dose-
intensive doxorubicin and cyclophosphamide; SD-CT, standard dose
chemotherapy. IBCSG Trial 15–95 QL schema (B). Patients were asked
to complete a QL core form plus a trial-specific module at baseline, during,
and following chemotherapy.
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sfrom 0 to 100, with higher scores indicating a better condition. We
report and plot the model-based mean estimates and the
corresponding 95% confidence intervals of the treatment effects
adjusted for patients’ culture (Hurny et al, 1996; Bernhard et al,
1998), age, and baseline score (see Table 1 for culture definitions).
We considered a change of X8 points on a scale of 0–100 as
clinically significant (Sloan and Dueck, 2004).
Quality-adjusted survival
We used the Q-TWiST model, which divides the lifespan of the
patients from the beginning of adjuvant treatment until death into
three time segments corresponding to distinct health states: TOX
(time with toxicity from adjuvant treatment), TWiST (time without
reported symptoms of treatment or disease), and REL (time
from first relapse until death) (Goldhirsch et al, 1989). To calculate
Q-TWiST, each health state is assigned a utility coefficient
(ut, utwist, and ur), which gives a value to time spent in the state
relative to the value of an equal amount of time spent in a state of
‘perfect health.’ The utilities are assumed to be in the interval (0,1),
where a zero indicates the worst possible health and one indicates
a state as good as perfect health. The Q-TWiST value is the linear
combination of the health state durations adjusted by the respective
utilities: Q-TWiST¼ut TOXþutwist TWiSTþur REL.
We calculated the time spent in the three health states for 324 of
the 344 randomised patients, that is, we excluded the 20 patients
who never received any of their prescribed chemotherapy (6 in the
SD-CT group and 14 in the DI-EC group). Toxicity was assessed
and collected during chemotherapy. One month was assigned to
TOX for any reversible subjective toxic effect (i.e., does not include
objective laboratory measures, e.g., blood count) of grade 3 or
higher reported during a cycle. Three additional months were
included after the last report of grade 3 or higher alopecia or
weight gain. Additional time was added to TOX for subjective
grade 3 and higher toxicities reported after chemotherapy ended
for 13 cases in the DI-EC group and 1 case in the SD-CT group.
Appendix A describes the QL-oriented end points and defines
toxicity included in this analysis.
All available SHE scores (Hurny et al, 1998) obtained from these
324 patients were used to calculate the utilities attached to each of
the three health state durations. For the first 18 months (Figure 1B)
and yearly from months 24 to 72, patients were asked to imagine
that they would have to live the rest of their life in their current
condition and then to rate this condition between ‘perfect health’
and ‘worst health.’ This indicator was previously validated against
a time trade-off interview in patients with metastatic breast cancer
(Hurny et al, 1998). Within each health state, we calculated the
median SHE score using all available scores averaged within
patients; that is, for TOX the first 6 months on SD-CT and months
2 and 3 on DI-EC. These health estimates were converted to quality
weights using a power transformation (Bernhard et al, 2004). As a
supplemental analysis, SHE scores were averaged separately within
those patients reporting any subjective grade 3 or higher toxicity
during chemotherapy. To account for the less than ‘perfect health’
during the TWiST state, we divided the utilities of both analyses by
the respective utwist so that Q-TWiST is interpreted relative to
TWiST: Q-TWiST¼(ut/utwist) TOXþ(utwist/utwist) TWiSTþ
(ur/utwist) REL.
Mean health state durations were estimated from censored
survival data (product limit method) up to 72 months from
randomisation by computing the areas between the survival curve
estimates for the transition times. These durations were adjusted
using the patient-derived utilities in order to estimate the mean
Q-TWiST for each treatment group. The variability of the patient-
derived utilities was not factored into this estimate. However, we
performed a threshold utility analysis for the full range of possible
utilities for TOX and REL.
P-values are two-sided. Pp0.05 were deemed statistically
significant and Po0.01 are reported as o0.01. No adjustment
was made for multiple testing.
RESULTS
Quality of life
The definition of the sample for the QL analysis is shown in
Table 1. Baseline characteristics were balanced according to
treatment arm (Table 2). Twenty-five percent of the patients were
less than 40 years old. Mastectomy was the primary surgery in 69%
of women while breast-conserving surgery was performed in 31%.
Radiotherapy was administered to 49% of the former group and
100% of the latter group. The QL form submission rates at baseline
and at 3, 6, 9, 12, and 18 months following randomisation were 78,
82, 78, 84, 82, and 85%, respectively. More patients in the SD-CT
group had baseline QL data (89 vs 68%); otherwise, the QL form
submission rates were similar between treatment arms. Partici-
pants and non-participants at month 18 were similar regarding
age, menopausal status, tumour size, tumour grade, and ER status
at random assignment.
There were no baseline differences between treatments (Table 3).
Baseline scores were most impaired for the primary QL end point
(coping effort) and also for secondary indicators, including the
thought of having treatment.
In both the SD-CT and DI-EC groups, the global QL indicators
showed a noticeable reduction while on treatment but a marked
improvement 3 months following chemotherapy to levels generally
exceeding those reported at baseline. This pattern across time was
more pronounced for DI-EC, as shown for coping effort and SHE
(Figure 2A and B, respectively). At the first month on treatment for
the SD-CT cohort, but before the DI-EC cohort received protocol
therapy, better scores were seen for patients receiving DI-EC as
compared with those receiving SD-CT. Substantial differences in
patient perception of side effects were present, particularly after
completion of the shorter DI-EC therapy, as shown for nausea/
vomiting and sore mouth (Figure 3A and B, respectively). Worse
scores for sore mouth were evident at months 2 and 3 for the
DI-EC cohort and better scores at months 5 and 6 following the
cessation of DI-EC treatment but before the end of SD-CT.
Patients’ overall estimates of treatment burden (Figure 3C) showed
a similar pattern, with worse scores for those with DI-EC at
months 2 and 3 (both Po0.01) and better scores at months 5 and 6
(P¼0.01 and o0.01, respectively).
Table 3 shows the estimated mean scores derived from the linear
mixed-effects models adjusted for patients’ culture, age, and
baseline score at selected time points for all QL indicators. This
analysis confirms that time had a major impact on patients’ QL,
which differed according to treatment. The time by treatment
interaction estimate was statistically significant for all indicators.
In particular, the improvement over time following chemotherapy
is seen on both arms, but a significantly larger and more rapid
Table 1 Description of patients excluded from the QL analysis
Remaining cases
Total cases 344
Exclusions from analysis:
Did not receive protocol treatment 20 324
Relapse within first 18 months of randomisation 72 252
Completed no QL assessments 3 249
Completed assessments in multiple languages 6 243
Abbreviations: QL¼quality of life. Culture is defined by the following language/
country combinations: English/Australia, New Zealand; French/Switzerland; German;
Italian/Italy; Slovenian/Slovenia; Hong Kong.
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srecovery is seen within the DI-EC cohort as compared with the
SD-CT cohort. For instance, the change in coping scores after
completion of therapy on the DI-EC arm improved by 25U from
month 3 to 6 (Po0.01), whereas on the SD-CT arm, coping scores
improved by 11U from month 6 to 9 (Po0.01). These changes in
coping exceeded the minimal clinical significance, with an average
improvement of 14U more in the DI-EC cohort compared with
those in the SD-CT cohort (Po0.01). There were similar treatment
differences in recovery by most of the other indicators (data not
shown). At month 9, there was no difference by treatment with the
exception of subjective health (P¼0.01). Patients in the DI-EC
cohort reported consistently better health estimates over the whole
follow-up (Figure 2B).
Quality-adjusted survival
Baseline characteristics for the 324 patients included in the
Q-TWiST analysis were balanced according to treatment arm
and were similar to the baseline characteristics of the 243
patients included in the QL analysis (Table 2). Unadjusted
disease-free and overall survival at 72 months median follow-up
are summarised in Table 4. Although the result was not statistically
significant, patients who received DI-EC had improved disease-
free survival compared with patients who received SD-CT
(P¼0.11).
The estimated utility coefficients derived from all available
patients for the TOX, TWiST, and REL states were 0.77, 0.91, and
Table 2 Baseline characteristics of the 243 patients included in the QL analysis and of the 324 patients included in the Q-TWiST-analysis
243 Patients included in the QL analysis 324 Patients included in the QAS analysis
DI-EC SD-CT Total DI-EC SD-CT Total
N (%) N (%) N (%) N (%) N (%) N (%)
Total cases 121 (100) 122 (100) 243 (100) 159 (100) 165 (100) 324 (100)
ER-negative 54 (45) 61 (50) 115 (47) 83 (52) 92 (56) 175 (54)
ER-positive 67 (55) 59 (48) 126 (52) 76 (48) 71 (43) 147 (45)
ER-unknown 0 (0) 2 (2) 2 (1) 0 (0) 2 (1) 2 (1)
Age o40 years 32 (26) 28 (23) 60 (25) 41 (26) 36 (22) 77 (24)
Age X40 years 89 (74) 94 (77) 183 (75) 118 (74) 129 (78) 247 (76)
Total mastectomy no. of RT 48 (40) 38 (31) 86 (35) 64 (40) 53 (32) 117 (36)
Total mastectomy+RT 41 (34) 42 (34) 83 (34) 55 (35) 55 (33) 110 (34)
Breast conservation no. of RT 0 (0) 0 (0) 0 (0) 0 (0) 1 (1) 1 (o1)
Breast conservation+RT 32 (26) 42 (34) 74 (31) 40 (25) 56 (34) 96 (30)
Premenopausal 81 (67) 84 (69) 165 (68) 107 (67) 111 (67) 218 (67)
Postmenopausal 40 (33) 38 (31) 78 (32) 52 (33) 54 (33) 106 (33)
Abbreviations: DI-EC¼dose-intensive epirubicin cyclophosphamide; QL¼quality of life; RT¼radiotherapy; SD-CT¼standard dose chemotherapy (AC 4-CMF 3).
Table 3 Mean estimates of each QL indicator from the (a) IBCSG Core Form and (b) trial-specific module by treatment group at months 0, 3, 6, 9, 12,
and 18 months from randomisation
a
Months from randomisation
0369 1 2 1 8
QL SD-CT DI-EC P-value SD-CT DI-EC P-value SD-CT DI-EC P-value SD-CT DI-EC P-value SD-CT DI-EC P-value SD-CT DI-EC P-value
(a)
Physical well-being 84±28 7 ±2 0.24 73±35 2 ±4 o0.01 75±38 4 ±3 0.01 88±28 7 ±2 0.76 89±28 9 ±2 0.90 88±29 0 ±2 0.30
Mood 74±37 4 ±3 0.95 74±36 4 ±4 0.01 76±38 4 ±3 0.02 85±28 3 ±2 0.51 86±28 7 ±2 0.71 88±28 9 ±2 0.52
Tiredness 76±37 8 ±3 0.42 56±44 6 ±5 0.05 59±47 3 ±4 o0.01 69±37 5 ±3 0.12 76±37 6 ±3 0.94 74±38 1 ±3 0.03
Appetite 89±29 0 ±2 0.60 81±35 8 ±4 o0.01 85±28 8 ±2 0.27 92±29 2 ±2 0.84 94±29 3 ±2 0.97 94±19 4 ±2 0.94
Hot flushes 93±29 4 ±2 0.65 84±39 0 ±3 0.05 76±47 9 ±4 0.60 68±47 1 ±4 0.44 68±47 7 ±4 0.05 63±57 0 ±5 0.16
Nausea/vomiting 96±19 8 ±1 0.23 74±37 4 ±3 0.83 84±29 6 ±1 o0.01 98±19 7 ±1 0.46 97±19 8 ±1 0.56 98±19 8 ±1 0.71
Coping effort 60±46 1 ±4 0.94 60±45 1 ±4 0.06 62±47 6 ±3 o0.01 73±37 8 ±3 0.12 77±37 8 ±3 0.83 78±38 3 ±3 0.09
Feel supported 97±19 7 ±1 0.87 93±19 6 ±1 0.04 93±19 6 ±1 0.07 94±19 4 ±1 0.91 93±19 4 ±1 0.40 93±19 5 ±1 0.18
Arm restriction 71±37 1 ±3 0.84 83±28 1 ±3 0.49 85±28 2 ±3 0.44 83±28 1 ±3 0.49 80±38 2 ±3 0.51 84±28 3 ±3 0.67
Subjective health 75±27 3 ±3 0.65 65±36 1 ±4 0.30 67±37 9 ±3 o0.01 75±38 3 ±2 0.01 79±28 4 ±2 0.06 80±28 6 ±2 0.01
(b)
Hair loss 94±29 6 ±1 0.24 36±53 4 ±6 0.79 83±38 5 ±3 0.63 94±29 3 ±2 0.63
Numbness 92±29 3 ±1 0.63 88±29 0 ±2 0.43 89±28 8 ±2 0.81 91±28 7 ±2 0.16
Thoughts 60±35 8 ±4 0.66 63±35 3 ±4 0.05 70±38 4 ±3 o0.01 89±28 9 ±2 0.83
Sexual interest 81±37 7 ±3 0.38 64±46 2 ±4 0.76 63±48 0 ±3 o0.01 79±38 3 ±3 0.28
Sore mouth 98±19 8 ±1 0.70 85±26 5 ±4 o0.01 90±29 6 ±1 0.01 97±19 8 ±1 0.58
Pain 90±29 1 ±2 0.74 88±28 4 ±2 0.11 88±29 1 ±2 0.34 90±29 2 ±2 0.44
Treatment burden 78±27 6 ±3 0.59 64±35 0 ±4 o0.01 68±38 1 ±3 o0.01 86±28 2 ±3 0.24
Daily activity 74±27 4 ±3 0.99 68±35 2 ±4 o0.01 73±37 9 ±3 0.06 82±28 4 ±2 0.49
Abbreviations: QL¼quality of life; DI-EC¼dose-intensive epirubicin cyclophosphamide; SD-CT¼standard dose chemotherapy (ACx4-CMFx3). Higher scores indicate a better
condition for all indicators.
aEstimates were obtained from a linear mixed-effects model adjusted for patients’ age, culture, and baseline score.
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s0.77, respectively (Table 5). Fifty-two percent of the patients
receiving DI-EC experienced at least one grade 3 or higher
subjective toxic side effect during chemotherapy; 18% on SD-CT.
For a more conservative estimate, we derived utility scores for
TOX from this subsample, which were similar to the total sample,
but more pronounced (ut¼0.70; Table 5).
Using the estimates of all available scores (ut¼0.77), the average
Q-TWiST for patients receiving DI-EC was 52.1 months, 1.8
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Figure 2 Mean estimates of coping (A) and SHE scores (B) by treatment group during the first 18 months. Estimates were obtained from a linear mixed-
effects model adjusted for patients’ age, culture, and baseline score. The points indicate the assessments when the patients were undergoing chemotherapy.
Higher values indicate less effort to cope or better health status (i.e., better condition).
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Figure 3 Mean estimates of nausea/vomiting (A), sore mouth (B), and overall treatment burden scores (C) by treatment group during the first 9 months.
Estimates were obtained from a linear mixed-effects model adjusted for patients’ age, culture, and baseline score. The points indicate the assessments when
the patients were undergoing chemotherapy. Higher values indicate less side effects or burden (i.e., better condition).
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6.1; Table 6). Similarly, using ut separately from those patients
reporting any subjective grade 3 or higher toxicity (ut¼0.70), the
average Q-TWiST for patients receiving DI-EC was 51.9 months,
again 1.7 months longer than for SD-CT (95% CI,  2.7 to 6.0).
In further analyses accounting for less than ‘perfect health’
during the TWiST state, the average Q-TWiST for patients
receiving DI-EC was 57.1 months, yielding a similar estimate of
2.0 months longer than for patients receiving SD-CT (95% CI,  2.8
to 6.7). The adjusted coefficients from those patients reporting any
subjective grade 3 or higher toxicity resulted in an average
Q-TWiST for patients receiving DI-EC of 57.1 months, 1.8 months
longer than for those receiving SD-CT (95% CI,  2.9 to 6.6).
Figure 4 displays the threshold plot comparing DI-EC to SD-CT,
which presents treatment comparisons for all possible values of the
utilities for TOX and REL, allowing the interpretation of the trial
results to be based on individual preferences. In order to visualise
the patients’ own perception of their health status (Table 5), the
overall estimated patient-rated utilities (ut¼0.77 and ur¼0.77)
have been superimposed. In addition, to illustrate the variability
around these overall estimates, we superimposed the patient-rated
utilities for those cases that experienced both grade 3 or higher
toxicity during chemotherapy and disease relapse (N¼23). The
diagonal lines indicate the units of months gained in Q-TWiST for
a given pair of TOX and REL utilities. For example, a conventional
treatment comparison for disease-free survival is restricted to the
TOX and TWiST states, which are valued the same (ut¼utwist¼1).
On the basis of these assumptions, there is a statistically
nonsignificant gain for DI-EC of less than 2 months. Taking into
account the different values for TOX (uto1) and TWiST
(utwist¼1) and including REL, Q-TWiST would favour DI-EC for
almost all values of ut and ur, although the results did not achieve
statistical significance.
DISCUSSION
We have compared QL indicators and quality-adjusted survival in
patients receiving a dose-intensive but shorter chemotherapy
regimen with those receiving a less toxic standard regimen. The
therapies showed distinctly different patterns, reflecting both the
delayed commencement and shorter duration of DI-EC. Patients
receiving both SD-CT and DI-EC showed rapid recovery in QL to
levels generally exceeding those recorded at baseline. Despite the
greater initial toxicity of the DI-EC regimen, there were minimal
treatment-related differences after completion of chemotherapy, a
finding consistent with previous trials (Macquart-Moulin et al,
2000; Del Mastro et al, 2002; Brandberg et al, 2003; Peppercorn
et al, 2005).
Because we wished to obtain detailed QL scores during
treatment, we used monthly QL assessments during chemotherapy
and the first 3 months of follow-up. This shorter schedule with
more frequent QL assessments revealed a time by treatment
interaction sensitive to the duration of treatment: patients
receiving DI-EC showed worse QL scores during the time of
chemotherapy but a faster recovery following the shorter duration
of treatment, while patients receiving SD-CT showed a less
pronounced worsening but a more protracted recovery. It is
possible that the marked improvement in coping during the initial
months after completing DI-EC reflects the relief and sense of
accomplishment that the patient may feel after undergoing a
difficult experience. Adaptation and thus time itself can have a
decisive impact on mental and physical functioning in early breast
cancer (Hurny et al, 1996; Helgeson et al, 2004), which may come
into play less under chemotherapy. Informing the patient about
this improved outlook is of great value when guiding her through
chemotherapy and caring for acute toxicity.
To evaluate trade-offs between QL and survival time, we used
utility scores derived from the SHE scale (Hurny et al, 1998)
during adjuvant therapy, disease-free interval, and after relapse
with the time spent in each state and performed a quality-adjusted
survival analysis. During the TOX and the TWiST states, the
patient-derived utility values were similar between the two
regimens. Although the utilities in the TWiST state were better
than during TOX, they were less than ‘perfect,’ comparable to
those in patients with node-negative disease receiving tamoxifen
only or three cycles of CMF (Bernhard et al, 2004). In addition to
the threat of a malignant disease, menopausal symptoms, fatigue
(Ganz et al, 2002; Fan et al, 2005; Nieboer et al, 2005), and
cognitive impairment (Phillips and Bernhard, 2003; Falleti et al,
2005; Stewart et al, 2006), and their secondary effects can impact
general well-being in the long run. For nearly all values of weights
applied to TOX or REL, because of recovery from the shorter
duration DI-EC therapy and its influence on delaying relapse, the
threshold utility analysis favoured DI-EC, further supporting the
clinical study’s overall conclusion (Basser et al, 2006).
Table 4 Unadjusted disease-free and overall survival by treatment at 72 months median follow-up for the 324
a patients included in the Q-TWiST-analysis
No. of patients No. of events 5-year DFS%±s.e. P-value No. of dead 5-year OS%±s.e. P-value
DI-EC 159 79 52±4 0.11 55 71±4 0.25
SD-CT 165 97 44±46 7 6 3 ±4
Abbreviations: DI-EC¼dose-intensive epirubicin cyclophosphamide; SD-CT¼standard dose chemotherapy (ACx4-CMFx3); DFS¼disease-free survival; OS¼overall survival;
s.e.¼standard error; P¼P-value.
aExcluding 20 patients who did not receive any of their prescribed treatment (6 in the SD-CT group and 14 in the DI-EC group).
Table 5 Patient-derived utility coefficients: overall and according to
treatment
Health state N
a SHE TTO¼1 (1 SHE)
1.6
Mean SHE scores within patients with SD-CT (months: 1, 2, 3, 4, 5, 6) or DI-EC
(months 2, 3)
TOX
Total sample 284 0.60 0.77
SD-CT 149 0.60 0.77
DI-EC 135 0.57 0.74
Mean SHE scores within patients reporting grade 3 or higher toxicity with SD-CT
(months: 1, 2, 3, 4, 5, 6) or DI-EC (months 2, 3)
TOX
Total sample 96 0.53 0.70
SD-CT 27 0.51 0.68
DI-EC 69 0.55 0.72
TWiST
Total sample 292 0.78 0.91
SD-CT 140 0.80 0.92
DI-EC 152 0.77 0.90
REL
Total sample 85 0.60 0.77
SD-CT 51 0.55 0.72
DI-EC 34 0.64 0.80
Abbreviations: DI-EC¼dose-intensive epirubicin cyclophosphamide; SD-CT¼
standard dose chemotherapy (ACx4-CMFx3); SHE¼subjective health evaluation;
TTO¼time trade-off.
aSample size reflects those patients who experienced
that health state and who responded to the SHE question at least once during
that health state.
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were no baseline differences. Under treatment, our findings are
confounded by the setting of care, that is, in-patient for DI-EC vs
out-patient for SD-CT, as reflected in the finding that patients in
the DI-EC group felt more supported during chemotherapy.
Overall, the pattern of QL differences between the two regimens
was consistent. Our QL follow-up was restricted to 18 months, and
thus we could not evaluate the long-term sequelae of the two
regimens.
We recommend complementing a QL analysis by patient-
weighted Q-TWiST analysis, particularly for phase III trials on
regimens with distinct toxicity profiles.
In conclusion, taking into account not only the extent of toxicity
during and following chemotherapy but also the duration, patients’
perception of the more intensive DI-EC regimen is more
favourable than that of SD-CT. Our findings may be generalised
for similar future dose-intensive regimens used in breast
cancer and those currently in use for other cancer sites (e.g.,
lymphomas). The role of shorter total time on chemotherapy with
some intense treatment regimens has implications for adaptation
but has not received the attention it deserves. In particular, the
rapid recovery of QL after a more toxic but shorter regimen needs
further study.
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DEFINITION OF QUALITY-OF-LIFE ORIENTED END POINTS
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